logo
Twitter
Discord
Email
logo
Nyxoah S.A.

Nyxoah S.A.

NASDAQ•NYXH
CEO: Mr. Robert Taub MBA
Sector: Healthcare
Industry: Medical - Instruments & Supplies
Listing Date: 2021-04-28
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Contact Information
Rue Edouard Belin 12, Mont-Saint-Guibert, 1435, Belgium
32-10-22-23-55
www.nyxoah.com
Market Cap
$177.01M
P/E (TTM)
-1.8
76.8
Dividend Yield
--
52W High
$11.87
52W Low
$4.35
52W Range
5%
Rank61Top 80.3%
2.4
F-Score
Modified Piotroski Analysis
Based on 8-year fundamentals
Weak • 2.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2017-2024

Financial Dashboard

Q3 2025 Data

Revenue

$2.31M+55.77%
4-Quarter Trend

EPS

-$0.74+26.00%
4-Quarter Trend

FCF

-$23.97M+44.28%
4-Quarter Trend

2024 Annual Earnings Highlights

Key Highlights

Revenue and Gross Profit Growth Revenue reached €4.5M, up 4%. Gross Profit increased 10% to €2.97M, driven by European commercialization.
DREAM Trial Primary Endpoint Met Pivotal DREAM trial met primary endpoints March 2024. PMA submission finalized, targeting US market availability Q1 2025.
Strengthened Cash Position Cash and equivalents totaled €34.2M as of December 31, 2024, providing at least 12 months funding runway.

Risk Factors

Internal Control Material Weaknesses Material weaknesses persist in internal controls related to insufficient accounting personnel and supervisory oversight.
Widening Operating Loss Operating loss widened 30% to €58.8M in 2024 due to increased R&D and SG&A expenses.
US Regulatory Approval Uncertainty US FDA marketing authorization timeline remains uncertain despite PMA submission completion; delays could impact growth.
Need for Future Capital Continued operating losses necessitate future capital raises, which may not be available on commercially favorable terms.

Outlook

US Market Launch Anticipated Expect FDA marketing authorization and commercial availability in the United States during the first quarter of 2025.
Expanding Commercial Footprint Continue investing in European sales teams and building US commercial organization capacity in anticipation of launch.
Product Pipeline Investment Investing in next-generation Genio 3.1 system development and expanding indications through ongoing clinical trials.
Focus on Favorable Reimbursement Pursuing favorable reimbursement coverage in key European markets to drive broad acceptance and adoption of the system.

Peer Comparison

Revenue (TTM)

Inogen, Inc.INGN
$347.03M
+4.7%
Neuronetics, Inc.STIM
$129.87M
+78.6%
Outset Medical, Inc.OM
$120.07M
+4.7%

Gross Margin (Latest Quarter)

Sangamo Therapeutics, Inc.SGMO
100.0%
+6804.2pp
Caribou Biosciences, Inc.CRBU
71.3%
-28.7pp
Nyxoah S.A.NYXH
60.5%
-1.4pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
TRDA$423.85M-4.4-26.4%12.7%
ENTA$314.67M-3.9-93.8%71.6%
PYXS$267.67M-2.8-102.1%18.1%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
19.6%
Strong Growth
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
0%
Cash Flow Needs Attention

Research & Insights

Next earnings:Mar 12, 2026
|
EPS:-$0.62
|
Revenue:-
Reports
All Years

  • Form 20-F - FY 2024

    Period End: Dec 31, 2024|Filed: Mar 20, 2025|
    Revenue: $4.89M+4.0%
    |
    EPS: $-1.96-16.8%
    Miss

  • Form 20-F - FY 2023

    Period End: Dec 31, 2023|Filed: Mar 20, 2024|
    Revenue: $4.70M+41.0%
    |
    EPS: $-1.68-28.1%
    Miss

  • Form 20-F - FY 2022

    Period End: Dec 31, 2022|Filed: Mar 22, 2023|
    Revenue: $3.24M+262.0%
    |
    EPS: $-1.27-4.3%
    Miss

  • Form 20-F - FY 2021

    Period End: Dec 31, 2021|Filed: Mar 24, 2022|
    Revenue: $1.01M+1134.8%
    |
    EPS: $-1.37-70.6%
    Miss